Carmen Clapp, Juan Pablo Robles, Magdalena Zamora, Gonzalo Martínez de la Escalera, Jakob Triebel, and Thomas Bertsch are inventors of the patent application entitled: Oligopeptide that inhibits angiogenesis and vascular function. Submitted in Mexico on November 20, 2019 (MX/E/2019/079075) and in the European Union on July 7, 2020 ( PCT/EP2020/069154). Published on May 27, 2021.(WO2021098996 ). With applications in EUA (US17/778,396; Exp. P2022/13828US), Japon (Exp. P2022/13827JP), China (Exp. P2022/13825CN) and Europe (EP20740261.1; Exp 109205320).
UNAM-Press release (Dirección General de Comunicación Social) regarding the development of vasoinhibin analogues with therapeutic potential.
The article entitled “The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide” was published
in Angiogenesis and notified as a relevant discovery by a German news agency.
First results from our clinical study protocol entitled:"Levosulpiride increases the levels of prolactin and antiangiogenic vasoinhibin in the vitreous of patients with proliferative diabetic retinopathy" were published in Translational Vision Science & Technology.
First Place of Farmaceutical Innovation Award 2021, 6a. Edition from the Mexican Pharmaceutical Council and UNAM Foundation
The abstract entitled "Levosulpiride for the treatment of diabetic macular edema: A phase 2, randomized, pilot clinical trial" received the 1st place Award in Innovation in Oftalmology in the Diabetic Retinopathy category by Grin Laboratories and Mexican Health Foundation and will be communicated as oral presentation at the 2023 Meeting of the Endocrine Society at Chicago Il.
The work by Georgina Ortiz and Jose Fernando García Rodrigo were selected for a travel award and will be communicated orally at the 2023 Meeting of the Endocrine Society in Chicago.
The work by Magdalena Zamora will be presented orally at the 2023 Meeting of the North American Society for Comparative Endocrinology (NASCE).
SELECTED AWARDS
Biotechnology Career Fellowship. Rockefeller Foundation (1989-1995); Fellow "John Simon Guggenheim Memorial Foundation (1994); Research Award of the Mexican Academy of Science (1995); Young researcher award UNAM (1995); International Research Scholar of the Howard Hughes Medical Institute (1997-2002); José Santos Ophthalmology Award (2001 and 2007); GEN award for research on defects at birth (2005 and 2008); Medical Research Award "Dr. Jorge Rosenkranz" Grupo ROCHE-SYNTEX (2006); Bienial Research Award on Ophthalmology (2006); Research award by the Mexican Chamber of Pharmaceutical Laboratories (CANIFARMA) (2008). Research Award in Diabetic Retinopathy, Mexican Health Foundation (2011). Lifetime Scientific Achievements Award, Queretaro University (2013). UNAM Award in Natural Sciences 2016 (PUN 2016). Clinical Investigation Award "Miguel Alemán Valdés" (2017). Award by the Program of Patent and Innovation (PROFOPI) 2020, UNAM. Women in Science 2021 Award to Carmen Clapp by L'Oreal-UNESCO-AMC. Emeritus Scientist of the National System of Researchers (SNI, 2022-). Farmaceutical Innovation Award 2021, 6a. Edition from Mexican Pharmaceutical Council and Health Foundation.
